KALA BIO, Inc. (KALA) Q4 2021 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Kala Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.049 -- 00:00:03.850 Good morning and welcome to the Call of Pharmaceuticals conference call to review its 00:00:03.850 -- 00:00:07.750 fourth quarter and full year 2021 financial results. 00:00:07.750 -- 00:00:11.311 At this time, all participants are in listen-only mode. 00:00:11.311 -- 00:00:15.412 Following management's prepared remarks, a Q&A session will be held. 00:00:15.412 -- 00:00:17.472 As a reminder, this call is being recorded. 00:00:17.472 -- 00:00:22.513 I would like to turn the call over to Jill Steyer, Executive Director, Investor 00:00:22.513 -- 00:00:26.174 Relations and Corporate Communications for Call of Pharmaceuticals. 00:00:26.174 -- 00:00:28.414 Please proceed. 00:00:29.363 -- 00:00:33.706 Thank you, Operator, and thank you all for participating in today's call. 00:00:33.706 -- 00:00:39.591 Joining me from the company are Mark Iwicki, Chairman and Chief Executive Officer, 00:00:39.591 -- 00:00:44.954 Todd Bazemore, President and Chief Operating Officer, Tim Brazel, 00:00:44.954 -- 00:00:50.438 Head of R&D and Chief Medical Officer, Mary Remeth, Chief Financial 00:00:50.438 -- 00:00:55.542 Officer, and Darius Karabi, our Chief Business Officer, will also be joining 00:00:55.542 -- 00:01:00.585 us for the Q&A portion of today's call. Today's call is being webcast 00:01:00.585 -- 00:01:05.969 live. The webcast link can be found in the investor section of our website at 00:01:05.969 -- 00:01:07.969 www.callrx.com. 00:01:10.252 -- 00:01:15.275 During this call, we will be referring to non-GAAP financial measures which are not prepared 00:01:15.275 -- 00:01:18.597 in accordance with generally accepted accounting principles. 00:01:18.597 -- 00:01:24.281 A reconciliation of the non-GAAP financial measures to the most direct comparable...